Full text is available at the source.
Abstract
De novo biosynthesis of psilocybin achieved 557.91 mg/L in shake flasks and 2.00 g/L in a bioreactor.
- Psychedelic-assisted therapy may be a promising option for treating depression.
- Psilocybin, found in magic mushrooms, is recognized for its effectiveness against PTSD and treatment-resistant depression.
- Current methods for extracting psilocybin are costly due to its low natural abundance.
- Artificial biosynthetic pathways in Escherichia coli could improve psilocybin production by bypassing a key enzyme.
- This approach may enhance the efficiency and commercial viability of psilocybin production.
Simplified